

**Product Name:** Cabergoline

**Catalog No.:** 2664

**Batch No.:** 2


CAS Number: 81409-90-7

IUPAC Name: *N*-[3-(Dimethylamino)propyl]-*N*-[(ethylamino)carbonyl]-6-(2-propenyl)ergoline-8-carboxamide

**1. PHYSICAL AND CHEMICAL PROPERTIES**

**Batch Molecular Formula:** C<sub>26</sub>H<sub>37</sub>N<sub>5</sub>O<sub>2</sub>  
**Batch Molecular Weight:** 451.6  
**Physical Appearance:** White solid  
**Solubility:** 1eq. HCl to 10 mM  
 DMSO to 100 mM  
 ethanol to 100 mM  
**Storage:** Store at +4°C

**Batch Molecular Structure:**



**2. ANALYTICAL DATA**

**HPLC:** Shows 100% purity  
**<sup>1</sup>H NMR:** Consistent with structure  
**Mass Spectrum:** Consistent with structure

**Microanalysis:**

	Carbon	Hydrogen	Nitrogen
Theoretical	69.15	8.26	15.51
Found	69.16	8.26	15.76

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

**Product Name:** Cabergoline

**Catalog No.:** 2664

**Batch No.:** 2

CAS Number: 81409-90-7

IUPAC Name: *N*-[3-(Dimethylamino)propyl]-*N*-[(ethylamino)carbonyl]-6-(2-propenyl)ergoline-8-carboxamide

**Description:**

Cabergoline is a selective D<sub>2</sub>-like dopamine receptor agonist (K<sub>i</sub> values are 0.7, 1.5, 9.0 and 165 nM for D<sub>2</sub>, D<sub>3</sub>, D<sub>4</sub> and D<sub>5</sub> receptors respectively) that also displays high affinity for several serotonin receptor subtypes (K<sub>i</sub> = 1.2 - 20.0 nM for 5-HT<sub>1A</sub>, 5-HT<sub>1D</sub>, 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub>). Inhibits secretion of prolactin and growth hormone and reverses levodopa-induced dyskinesias in Parkinsonian monkeys.

**Physical and Chemical Properties:**


Batch Molecular Formula: C<sub>26</sub>H<sub>37</sub>N<sub>5</sub>O<sub>2</sub>

Batch Molecular Weight: 451.6

Physical Appearance: White solid

**Minimum Purity:** ≥99%

**Batch Molecular Structure:**



**References:**

**Kvernmo et al** (2006) A review of the receptor-binding and pharmacokinetic properties of DA agonists. *Clin. Ther.* **28** 1065. PMID: 16982285.

**Hadj Tahar et al** (2000) Sustained caberg. treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. *Cin. Neuropharmacol.* **23** 195.

**Eguchi et al** (1995) Effect of cabergoline, a DA agonist, on estrogen-induced rat pituitary tumors: in vitro culture studies. *Endocr. J.* **42** 413. PMID: 7670571.

**Storage:** Store at +4°C

**Solubility & Usage Info:**

1eq. HCl to 10 mM  
DMSO to 100 mM  
ethanol to 100 mM

**Stability and Solubility Advice:**

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

**SOLIDS:** Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

**SOLUTIONS:** We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

**bio-techne.com**

info@bio-techne.com  
techsupport@bio-techne.com

**North America**

Tel: (800) 343 7475

**China**

info.cn@bio-techne.com  
Tel: +86 (21) 52380373

**Europe Middle East Africa**

Tel: +44 (0)1235 529449

**Rest of World**

www.tocris.com/distributors  
Tel: +1 612 379 2956